Taurine supplemented cell culture medium and methods of use
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsAmy S. Johnson, Meghan E. Casey, Shadia Oshodi, Shawn Lawrence
Life of this patent
Estimating the term…
Abstract
The specification describes a composition comprising an improved eukaryotic cell culture medium, which can be used for the production of a protein of interest. TaXULne can be added to the serum-free media or chemically-defined media to increase the production of a protein of interest. Methods for recombinantly expressing high levels of protein using the media compositions are included.
Claims30
A method for culturing recombinant eukaryotic cells for improved production of a recombinant protein of interest, comprising the steps of:
- (a) propagating recombinant eukaryotic cells in a defined cell culture medium during a growth phase;
- (b) supplementing the defined cell culture medium with at least 0.1 mM L-taurine and at least 2.4 mM arginine;
- and
- (c) expressing the recombinant protein of interest during a production phase,
- wherein the addition of L-taurine increases the titer of the recombinant protein of interest by at least 3% when compared to cells expressing the recombinant protein of interest in a cell culture medium containing less than 0.1 mM L-taurine.
A method for culturing recombinant eukaryotic cells for improved production of aflibercept, comprising the steps of:
- (a) propagating recombinant eukaryotic cells in a defined cell culture medium during a growth phase;
- (b) supplementing the defined cell culture medium with about 0.1 mM to about 10 mM L-taurine and about 2.4 mM to about 11.9 mM arginine;
- and
- (c) expressing aflibercept during a production phase,
- wherein the addition of L-taurine increases the titer of aflibercept by at least 3% when compared to cells expressing aflibercept in a cell culture medium containing less than 0.1 mM L-taurine.
A method for culturing recombinant eukaryotic cells for improved production of dupilumab, comprising the steps of:
- (a) propagating recombinant eukaryotic cells in a defined cell culture medium during a growth phase;
- (b) supplementing the defined cell culture medium with about 0.1 mM to about 10 mM L-taurine and about 2.4 mM to about 11.9 mM arginine;
- and
- (c) expressing dupilumab during a production phase,
- wherein the addition of L-taurine increases the titer of dupilumab by at least 3% when compared to cells expressing dupilumab in a cell culture medium containing less than 0.1 mM L-taurine.
Dependencies are inferred from the claim text.